Drug Database
Back to search

Netherlands· NL-029f02af6eb0

EXBLIFEP 2 g/0,5 g, poeder voor concentraat voor oplossing voor infusie

A cefepim und beta-lactamase-inhibitor product containing cefepimedihydrochloride 1-water + enmetazobactam, registered in Netherlands by Advanz Pharma Limited. The same ATC class is registered in 9 of our 19 countries.

ATC J01DE51

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedEXBLIFEP 2 g/0,5 g, poeder voor conce…ATCJ01DE51REGISTER NO.NL-029f02af6eb0PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about cefepimedihydrochloride 1-water + enmetazobactamAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Cefepim und beta-lactamase-inhibitor is registered in 9 of 19 countries.

Countries holding a registration under ATC J01DE51 (cefepim und beta-lactamase-inhibitor), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose
Search cefepim und beta-lactamase-inhibitor products by name

Cefepim und beta-lactamase-inhibitor · ATC J01DE51

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
CEFEPIMEDIHYDROCHLORIDE 1-WATER + ENMETAZOBACTAM
Manufacturer
Advanz Pharma Limited
Country
Netherlands (NL)
ATC code
J01DE51
ATC class
Cefepim und Beta-Lactamase-Inhibitor
Defined daily dose
6 g, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/24/1794

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Cefepim und beta-lactamase-inhibitor in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cefepim und beta-lactamase-inhibitor products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Exblifep
  • Liechtenstein · Exblifep
  • Norway · Exblifep

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b2df14ec-117e-40a7-b531-fae89ce9124c
GET /v1/drugs/b2df14ec-117e-40a7-b531-fae89ce9124c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/exblifep-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Cefepime and Beta-Lactamase Inhibitor",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130782",
  "excipients": [
    "ARGININE, (L-)",
    "STIKSTOF (HEAD SPACE) (E 941)"
  ],
  "substances": [
    "CEFEPIMEDIHYDROCHLORIDE 1-WATER",
    "ENMETAZOBACTAM"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/03/21",
  "procedure_number": "EMEA/H/C/005431",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/24/1794",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about cefepim und beta-lactamase-inhibitor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console